Trials / NCT06076720
Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision
Status unknown N/A Device
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Treatment
- New head-mounted visual aids
- Gene
- Not stated
- Conditions
- Glaucoma, Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy
- Ages
- 10 Years to 80 Years
- Enrollment
- 50 participants
- Started
- 2023-10-10
- Main results expected
- 2024-08-10
- Results posted
- Not yet
- Record last updated
- 2023-10-11
What the study is testing
Glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa, RP, diabetic retinopathy (DR) are the most common blinding eye diseases in the world. Vision and visual field are often severely impaired, quality of life is reduced, and personal and family burdens are heavy. This kind of low vision people, can use visual AIDS and other instruments for visual rehabilitation training, maximize the function of residual vision, improve the quality of life. Beyes, HOLA, Acesight and OXSIGHT are among the latest eyeglasses devices that are expected to improve the quality of life for people with low vision. This research group intends to recruit advanced patients with primary glaucoma, AMD, RP, DR and other common blinding eye diseases who visited Zhongshan Ophthalmology Center of Sun Yat-sen University from June 2021 to December 2022 to study the changes of visual function and quality of life after wearing this new type of head-worn visual aids, and analyze relevant factors combined with clinical data. To evaluate the effect and influencing factors of the new head-mounted visual AIDS on patients, and provide theoretical basis for subsequent clinical research.
Where it runs
China (1)
- Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong